

The complete non-invasive solution for advanced liver disease assessment





Powered by

LSM* by VCTE™

Liver Fibrosis

LSM by VCTE™ is unique, patented and validated for liver fibrosis assessment.

- It is the standard for non-invasive evaluation of liver stiffness.¹
- 2,250 peer-reviewed publications support the use of LSM by VCTE™.

CAPTM**

Liver Steatosis

CAPTM is unique, patented and validated for liver steatosis assessment.

• 330 international and peer-reviewed articles support the use of CAPTM.^{2,3}

SSM* by VCTETM

Portal hypertension

SSM by VCTE™ is unique, patented and validated for portal hypertension assessment and can be used for risk stratification of patients with advanced CLD.⁴

- It is a new marker for non-invasive evaluation of spleen stiffness.
- 50 peer-reviewed publications support the use of SSM by VCTE™

Touchscreen & washable touch keyboard

Redesigned ergonomics

The complete non-invasive solution for advanced liver disease management

Expand clinical capabilities with spleen stiffness measurement and ultrasound localization system.

Enhance exam efficiency with improved ergonomics and high-speed processing.



New intuitive user interface

High-speed processing

Integrated barcode reader

Ultrasound localization probe: time-saving technology for locating the spleen and liver in obese and complex patients

What makes FibroScan® unique?

Fast

A painless exam performed in less than 10 minutes to provide immediate results at the point-of-care.

Intuitive

Can be performed by any trained operator (physician, nurse).

Best in Class

The non-invasive gold standard solution validated by 2,400+ peer-reviewed publications and 60+ international guidelines.

Reliable

Standardized examination with exceptional precision and reproducibility that can be utilized in 99% of patients.^{2,3}

Original

Equipped with patented technology and proprietary algorithms to deliver consistently accurate results.

When evidence matters and consistency counts

- Pioneer in the field of liver elastography
- FibroScan® produces biomarkers that can assess and monitor patients over time
- FibroScan® uses uniform algorithms that minimize inter-operator variability and eliminate inter-system variability
- 6,500+ FibroScan® installed worldwide enabling millions of liver examinations
- Winner of the Red Dot Design Award (FibroScan® 430 Mini+ model)





Optimize clinical workflows with real-time secure data transmission

Save time, secure data, and improve patient follow-up with FibroScan® Gateway. FibroScan® Gateway acts as an integration engine, automatically uploading and storing examinations to the EHR (Electronic Health Record).







Enhancing FibroScan® liver disease assessment with biological markers

FAST

The optimal point-of-care comprehensive test for the identification of at risk **NASH** patients

FIBROMETER VCTE

Cutting-edge liver fibrosis assessment with FibroScan® and biological markers

FIBROMETER"

The benchmark blood test for liver fibrosis diagnosis and disease stratification

Interpretation Guide

Enhanced clinical decision support

The Interpretation Guides utilize data from clinical studies to assist providers in interpreting FibroScan® examination results.

- Available on -



Your everyday FibroScan® companion











The non-invasive gold standard solution for comprehensive management of liver health

Which FibroScan® is right for you?









FibroScan[®]

FibroScan[®]

FibroScan*

FibroScan[®]

Capabilities	LSM by VCTE™	~	V	~	~
	CAP™*		~	~	~
	SSM by VCTE™				~
Features	FibroScan® Gateway compatibility	~	~	~	~
	MyFibroScan® compatibility	~	~	~	~
	Embedded ultrasound localization system for assessment of obese or complex patients				~
	High-speed processing				~
	Integrated barcode reader				~
Ergonomics	Versatile and adaptive design: from transportable to cart-based device with dedicated roll stand			~	
	Fully transportable	~	~		
	Battery-powered	~	~	~	
	Weight	5 kg	5 kg	10 kg	46 kg

*Additional cost



because liver health matters

Products in the FibroScan® range are Class IIa medical devices as defined by Directive 93/42/EEC (EC 0459). These devices are designed for use in a medical practice in order to measure liver stiffness and ultrasound attenuation in patients with liver disease. Examinations with FibroScan® device shall be performed by an operator who has been certified by the manufacturer or its approved local representative. Operators are expressly recommended to carefully read the instructions given in the user manual and on the labelling of these products. Check cost defrayal conditions with paying bodies. Products FibroMeter™ are in vitro diagnostic medical devices as defined by Directive 98/79/EC. These scores, based on blood parameters, are useful tools for diagnosing and measuring the extent of liver fibrosis in patients with chronic liver disease of viral (including HIV co-infection), alcohol-related, or metabolic origin. FibroMeter™, FibroMeter VCTE™ FAST™ and FibroScan® are registered trademarks of Echosens. This marketing material is not intended for US audience. © Copyright Echosens - All rights reserved – Brochure FibroScan® 630 Expert v10720

^{1.} European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado, EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of live

^{1.} European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264. doi:10.1016/j.jhep.2015.04.006.

2. Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-1030. doi:10.1016/j.jhep.2016.12.022

3. Recio E, Cifuentes C, Macías J, et al. Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography. Eur J Gastroenterol Hepatol. 2013;25(8):905-911. doi:10.1097/MEG.0b013e32835f4c3d

^{4.} Stefanescu H, Marasco G, Calès P, et al. A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices. Liver Int 2020;40(1):175-185. doi:10.1111/liv.14228